Sildenafil does not alter nelfinavir pharmacokinetics

Area of Science:

• Pharmacology
• Drug Interactions
• HIV Therapeutics

Background:

• Nelfinavir is an antiretroviral medication used to treat HIV infection.
• Understanding potential drug interactions is crucial for optimizing HIV treatment regimens.
• Sildenafil is a medication commonly used for erectile dysfunction.

Purpose of the Study:

• To determine if sildenafil affects the pharmacokinetic profile of nelfinavir.
• To assess the safety and efficacy of co-administering sildenafil with nelfinavir in HIV-infected patients.

Main Methods:

• A pharmacokinetic study involving five HIV-infected patients on stable nelfinavir therapy.
• Nelfinavir concentrations were measured twice: once without sildenafil and once after a single 25 mg dose of sildenafil.
• Additional pharmacokinetic assessments were performed in patients on indinavir and ritonavir/saquinavir regimens.

Main Results:

• No significant differences were observed in the area under the curve (AUC), time to maximum concentration (Tmax), or maximum concentration (Cmax) of nelfinavir when co-administered with sildenafil.
• Pharmacokinetic profiles of indinavir and ritonavir/saquinavir were also unaffected by concomitant medications, consistent with existing literature.
• The study demonstrated no impact of sildenafil on nelfinavir's absorption, distribution, metabolism, or excretion.

Conclusions:

• A single dose of sildenafil does not alter the pharmacokinetics of nelfinavir in HIV-infected patients.
• Concomitant use of sildenafil with nelfinavir is unlikely to require dosage adjustments.
• These findings support the safe co-administration of sildenafil and nelfinavir in clinical practice.